Summary The anti-tumour antibody-dependent cell-mediated cytotoxicity (ADCC) capacity of the conventional antibody ml7-IA was compared with its chimerised analogue c17-lA and a newer chimeric antibody. cSF25. specific for colonic adenocarcinoma. The results (AUC units±s.e.m.. control versus cancer) show that mononuclear cells from patients with adenocarcinoma mediate ADCC as efficiently as those from controls for m17-lA (143 ± 14 vs 153 ± 14). c17-1A (174 16 vs 189 ± 14) cSF25 (215 ± 18 vs 237 ± 13) and effectors and targets alone (57 ± 9 vs 51 ± 8). Both chimeric antibodies mediated ADCC more effectively than ml 7-lA with cSF25 consistently producing the highest lysis. Furthermore, more efficient ADCC was found to correspond with monocyte activation examined flow cytometrically. The results (mean channel fluorescence) show that HLA-DR expression is increased with c17-lA (1436 + 200) and cSF25 (2252 ± 298) above that observed when effectors and targets were incubated alone (1157 ± 168) or with m17-IA (1286 + 170). Similarly. interleukin 2 receptor (IL-2R) expression (percentage of positive cells) was augmented in the presence of m17-lA (15 3). c17-lA (14 ± 3) and cSF25 (25 ± 3) when compared with no antibody (9 ± 2). We discuss the possibility that the superior ADCC activity of chimeric antibodies, especially cSF25. may be due to increased monocyte activation.
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The administration of murine monoclonal antibodies (MAbs) in humans for diagnostic and therapeutic purposes has been limited by their short circulating half-life and immunogenicity. Murine MAbs have circulating half-lives of 15-30 h in humans (Pimm et al.. 1985; Khazaeli et al., 1988) and thus may require frequent. repeated administration (Khazaeli et al., 1988) . In addition. the majority of patients develop an immune response to this foreign protein that is manifested by the appearance of circulating human anti-mouse antibodies (HAMAs) 10-30 days following exposure (Sears et al., 1982) . This HAMA response has been reported to alter pharmacokinetics and prevent circulating of the murine antibody and may lead to allergic reactions (Pimm et al., 1985; Khazaeli et al., 1988) .
In an attempt to overcome these problems, chimeric antibodies have been produced. These are genetic constructs having the variable region of mouse MAbs and the constant regions of human immunoglobulins (Morrison et al., 1984) . Chimeric antibodies have similar binding affinity (Sun et al., 1987; Buschbaum et al.. 1990 ) to their murine counterparts as well as a similar (Liu et al., 1987a; Shaw et al., 1987 Shaw et al., , 1988 or supenor (Liu et al., 1987b; Nishimura et al., 1987; Massucci et al.. 1988 ) ability to mediate cell-mediated cytotoxicity. These molecules have been shown to have improved biological activity and longer circulating half-lives and most appear to have reduced immunogenicity in humans (LoBuglio et al., 1989) .
Monoclonal antibodies directed against tumour-associated antigens may bring about tumour lysis by antibody-dependent cell-mediated cytotoxicity (Herlyn et al., 1979) . Although most MAbs used as anti-cancer agents are tumour selective, they are not tumour specific and may bind to non-malignant tissue, reducing their therapeutic efficacy and potentially increasing cytotoxicity. We therefore examined a recently developed chimeric antibody, cSF25, which appears to be more specific for colorectal cancer, for its ability to mediate ADCC (Takahashi et al., 1988 (Takahashi et al., , 1989 . We compared it with the anti-colorectal cancer antibodies, murine 17-lA (ml7-lA) and chimeric 17-lA (c17-4A), which are known to bind to normal colonic mucosa as well as to gastrointestinal adenocarcinomas (Gottlinger et al., 1986; Sun et al., 1987 (Gottlinger et al., 1986; Sun et al., 1987; Takahashi et al., 1988 Takahashi et al., , 1989 (Dye et al.. 1991) . The results are therefore expressed as AUC units ± standard error of the mean.
All three anti-colorectal antibodies and non-specific control antibodies were tested in parallel within the same experiment using lymphocytes from either cancer patients or healthy subjects. The experiment was repeated on two further colorectal cell lines, SWI116 and Colo320, to ensure that any result observed with LS180 was not cell line specific. For these experiments. PBMCs from control subjects were used. There were two groups of nine healthy volunteers who had not been studied previously. (Table   II) . Comparison of ADCC capacity for each antibodWe found a consistent and significant pattern with the antibodies in their ability to mediate ADCC (Figures 1 and 2 ). In patients with adenocarcinoma, when compared with effector cells alone, ml 7-lA. cI7-IA and cSF25 produced significantly better tumour lysis. c17-IA was superior to ml7-lA and cSF25 was significantly better than either ml7-la or c17-IA (Figure 1) . Similarly, in the control group, the pattern was the same (Figure 2 ). The AUC units approximated to levels of cytotoxicity of roughly <10% for effectors only. 20-30% for m17-iA, 30-40% for c17-4A and 50-60% for cSF25.
The non-specific control antibodies did not produce an increase in tumour lysis above that seen in the absence of antibody (Figure 3) . The murine irrelevant antibody, RI 1 DI0. produced approximately the same level of killing as that seen with effector cells alone. Surprisingly, the chimeric antibody c7E3 produced less killing than effector cells alone. We have not investigated this further, but since this antibody binds to platelet membranes the reduced cell lysis may possibly be due to platelet aggregation producing steric hindrance of the ADCC reaction.
Comparison of ADCC capacity between cell lines Small patient groups (n = 9) were used to test the ADCC assay in two additional colorectal cell lines, SW I I 6 and Colo321, and in each case the pattern of antibody-mediated lysis was the same as that observed with LS180 in the larger patient groups. Using Colo320 (Figure 4 ), tumour cell lysis was significantly greater with cSF25 (339 ± 12), cl7-IA (174 ± 28) and m17-lA (147 ± 29) than when effector cells alone (70 ± 16) were used. Similarly, with SWiI 16 ( Figure  5 ). cSF25 (296 ± 18), c17-iA (257 ± 24) and mi7-iA (196 + 16) produced significantly more tumour lysis than in the absence of antibody (65 ± 13). Figure 5 AUC units for ADCC mediated by ml7-lA. c17-lA and cSF25 against the cell line SWI 116. Results show mean value ± se.m. for nine control subjects. *Increase above no antibody (P<0.0001). tincrease above ml7-lA (P<0.0001). +Increase above m17-la and c17-JA (P<0.002).
presence of either c17-lA (1,437 ± 200) or cSF25 (2,252 299) antibodies dunrng the 18 h incubation period produced a significant increase above this value. Furthermore, cSF25 (2,252 ± 299) produced a level of HLA-DR expression that was significantly greater than either 17-lA antibody ( Figure  6 ). Monocyte IL-2 receptor expression was significantly increased in the presence of each of the three antibodies (Figure 7 ). When compared with no antibody (8.93 ± 2.44), ml7-lA (15.32±2.94), c17-lA (14.30±2.76) and cSF25 (25.56 ± 3.15) produced increased expression. In addition, the presence of cSF25 during the incubation period induced significantly greater IL-2 receptor expression than either ml 7-IA or c17-lA.
Discus
Monoclonal antibodies are thought to bring about tumour cell destruction via antibody-dependent cell-mediated cytotoxicity (Herlyn et al., 1979) . By this mechanism, effector cells expressing receptors for the Fc portion of IgG specifically bind to antibody attached to target cells and mediate lysis (Steplewski et al., 1983 (Steplewski et al., , 1988 Lubeck et al., 1985; Graziano & Fonger, 1987) . In order for a monoclonal antibody to bring about ADCC, it must recognise an epitope on the tumour cell surface and ideally, for therapeutic and diagnostic purposes, this antigen should be tumour specific. The chimeric antibody used in this study. cSF25, was pro- (Takahashi et al., 1988) . In contrast, the 17-lA antigen is known to be expressed on both normal colonic mucosa as well as on adenocarcinomas of gastrointestinal orgin (Gotlinger et al., 1986; Sun et al., 1987) . We examined tumour lysis in vitro by comparing the ability of this new antibody, cSF25, to mediate ADCC with the ability of conventional 17-lA antibodies using PBMCs derived from patients with mainly colorectal cancer. The results shown that the chimeric antibodies, c17-lA and cSF254, were both more effective in mediating tumour cell lysis than the murine antibody, m17-lA. This superior antitumour effect of chimeric 17-lA compared with ml7-lA has previously been demonstrated (Massucci et al., 1988 Previous reports have suggested that ADCC capacity may be either reduced (Stratton et al.. 1977; McCredie. 1979) or increased (Hersh et al.. 1982) The results demonstrate an increased expression of both HLA-DR and IL-2R, confirming significant monocyte activation in the presence of each of the three anti-colorectal monoclonal antibodies. This was especially apparent with the two chimeric antibodies, cl7-lA and cSF25. cSF25 significantly increased expression of both HLA-DR and IL-2R above either ml 7-lA or c17-lA. and it is tempting to suggest that the ability of cSF25 to mediate high levels of ADCC may be due to this superior ability to activate monocytes. This activation may be either direct or via cytokines produced by other cells within the PBMC population. These monocytes may then in turn produce tumour lysis via cytokine-mediated cellular cytotoxicity or by a direct mechanism. Studies are in progress to determine the role of the monocyte-derived cytokines, tumour necrosis factor alpha and interferon gamma in the ADCC assay in an attempt to clarify this point.
Although we have specifically examined activation markers present on monocytes, the effector cell population studied was not a pure monocyte preparation. There may therefore be an additional antibody effect on other cell populations which has not been elucidated here. A mixed population of effector cells is more analogous to the in vivo state, but our conclusions must be limited until we repeat this study utilising a pure monocyte preparation.
Chimeric monoclonal antibodies were engineered in the hope that they would reduce HAMA production and allergic reactions. We have demonstrated that in vitro the anticolorectal chimeric antibodies tested are more efficient at mediating antibody-dependent tumour lysis than their murine counterparts, which supports their use as a therapeutic option. Furthermore. this occurs as effectively with effector cells derived from patients with malignancy as with those from their normal healthy counterparts. suggesting that this effect will remain in patients with malignancy. In addition. we have shown that cSF25 has superior tumour lytic ability than the other antibodies tested. Since this antibody has been demonstrated to be a more specific antibody for colorectal cancer, it may be a promising therapeutic agent since the lack of target specificity of many monoclonal antibodies is thought to be partly responsible for their disappointing therapeutic effect in vivo. Finally, the data also suggest that efficiency of ADLCC is reflected by increased monocyte activation. and this may provide a possible target for in vivo augmentation of ADCC. However, whether this monocyte activation is important in mediating tumour cell lysis is a focus of further investigation.
